![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1463716
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀå Àü¸Á(-2030³â) : Áö¿ªº° ºÐ¼® - °Ë»ç À¯Çü, ±â¼ú ¹× À¯Åë ä³Îº°Asia Pacific Direct-to-Consumer Genetic Testing Market Forecast to 2030 - Regional Analysis - by Test Type, Technology, and Distribution Channel |
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀåÀº 2022³â 3¾ï 5,424¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2030³â¿¡´Â 15¾ï 3,084¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022-2030³â°£ 20.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.
SNP(Single Nucleotide Polymorphism) Ĩ äÅà Ȯ´ë, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀå ¼ºÀå ÃËÁø
ÃÖ±Ù ¸î ³âµ¿¾È °úÇÐÀû Áö½Ä Áõ°¡¿Í ÇÔ²² ÀüÅëÀû ÀÇ·á¿¡¼ °³ÀÎ ¸ÂÃãÇü ÀÇ·á·Î ÆÐ·¯´ÙÀÓÀÇ ÀüȯÀÌ ²ÙÁØÈ÷ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È´Â À¯Àü°øÇÐÀÇ ¹ßÀü, ´ÜÀÏ¿°±â´ÙÇü¼º(SNP) À¯ÀüÀÚÇü ºÐ¼®, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ¿Í ¹ÙÀÌ¿ÀĨ ±â¼úÀÇ ³ôÀº äÅÿ¡ ±âÀÎÇÕ´Ï´Ù. ¼ö½Ê¸¸ °³ÀÇ SNP¸¦ °¡Áø À¯ÀüÀÚ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ºÐ¼® Ç÷§ÆûÀÇ µµÀÔÀº °³ÀÎ °£ÀÇ º¸´Ù ½ÉÃþÀûÀÎ °èº¸ °ü°è¸¦ º¸´Ù °³¹æÀûÀ¸·Î °Ë»çÇÒ ¼ö ÀÖ´Â °í±Þ ¾Ë°í¸®ÁòÀÇ µµÀÔÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ, ¾Ç¼º Á¾¾ç °ËÃâ¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼Ò¾Æ°ú ¿µ¿ª¿¡¼´Â SNP µ¹¿¬º¯À̸¦ ´ë·® °á¼ÕÀ¸·Î ÇÏÀ̺긮µåÈÇÒ ÇÊ¿ä ¾øÀÌ ´Ü½Ã°£¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù´Â Á¡ÀÌ ¾öû³ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ´õ ¸¹Àº À¯ÀüÀÚ ÀÌ»óÀÌ ¹ß°ßµÇ°í Ä¡·áµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç ½ÃÀåÀº ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°íÈ¿À²°ú Á¤È®¼ºÀ» °®Ãá SNP ĨÀº ±â¼úÀûÀ¸·Î ´õ¿í Á¤±³Çϰí Á¤±³ÇÑ DTC À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ²÷ÀÓ¾ø´Â ¿ä±¸·Î ÀÎÇØ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, SNP Ĩ¿¡ ´ëÇÑ ³ôÀº ¼±È£µµ´Â ¾Ï ¿¬±¸¿¡ ÇʼöÀûÀÎ SNP ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ºÐ¼®°ú °°Àº ´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß¿Í ¿ë·® º¯È ¹× DNA ´ÙÇü¼º ÃøÁ¤ ´É·Â¿¡ ±âÀÎÇÕ´Ï´Ù. ¿ë·® º¯È ¹× DNA ´ÙÇü¼ºÀ» ÃøÁ¤ÇÒ ¼ö ÀÖ´Â ´É·Â¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, DTC À¯ÀüÀÚ °Ë»ç¿¡¼ ¿À·ù¸¦ ÃÖ¼ÒÈÇØ¾ß ÇÒ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó SNP ±â¼úÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ¿© ½ÃÀå ¼ºÀåÀÇ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀå °³¿ä
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ¼¼ºÐȵ˴ϴÙ. ÀÌ Áö¿ª ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È Àü ¼¼°è ÁÖ¿ä Áö¿ª Áß °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀåÀÇ È®»êÀº ¿ì¼öÇÑ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, À¯Àü¼º ÁúȯÀÇ Á¶±â °ËÁø¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¿¬±¸ °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÁýÁßµµ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, À¯ÀüüÇÐ ¿¬±¸ ¹× °³¹ßÀÇ ±ÞÁõ, ¸¹Àº ȯÀÚ Ç®, ÀÇ·á ÀÎÇÁ¶óÀÇ ¾÷±×·¹ÀÌµå µîÀº ¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀåÀÇ ¼ºÀå¿¡ À¯¸®ÇÏ°Ô ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀå ¼¼ºÐÈ
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀåÀº °Ë»ç À¯Çü, ±â¼ú, À¯Åë ä³Î, ±¹°¡º°·Î ±¸ºÐµË´Ï´Ù.
°Ë»ç À¯Çü¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀåÀº Á¶»ó °Ë»ç, ¿¹Ãø °Ë»ç, ¿µ¾çÀ¯ÀüüÇÐ °Ë»ç, ¿î¹Ýü °Ë»ç, ±âŸ·Î ±¸ºÐµÇ¸ç, 2022³â¿¡´Â °¡°è °Ë»ç ½ÃÀå ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±â¼ú Ãø¸é¿¡¼ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀåÀº Àüü °Ô³ð ½ÃÄö½Ì, ´ÜÀÏ ¿°±â ´ÙÇü¼º Ĩ, Ç¥Àû ºÐ¼®, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ´ÜÀÏ¿°±â´ÙÇü¼º Ĩ ºÎ¹®ÀÌ 2022³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀåÀº ÆÇ¸Å ä³Î¿¡ µû¶ó ¿Â¶óÀΰú ¿ÀÇÁ¶óÀÎÀ¸·Î ³ª´¹´Ï´Ù. ¿Â¶óÀÎ ºÎ¹®ÀÌ 2022³â Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. Áß±¹Àº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DTC(Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
Genesis Healthcare Co., Ancestry Genomics Inc, Myriad Genetics, Inc, Living DNA Ltd, 23andMe Inc, Genetic Technologies Ltd. Direct-To-Consumer) À¯ÀüÀÚ °Ë»ç ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ Áß ÀϺÎÀÔ´Ï´Ù.
¸ñÂ÷
The Asia Pacific direct-to-consumer genetic testing market was valued at US$ 354.24 million in 2022 and is expected to reach US$ 1,530.84 million by 2030; it is estimated to grow at a CAGR of 20.1% from 2022 to 2030.
Growing Adoption of Single Nucleotide Polymorphism (SNP) Chips Fuels the Asia Pacific Direct-to-Consumer Genetic Testing Market
There has been a steady paradigm shift from traditional medicine to personalized medicine with increasing scientific knowledge in recent years. This shift is due to advances in genetic engineering, single nucleotide polymorphism (SNP) genotyping, and the high adoption of microarrays and biochip technologies. The introduction of genetic microarray analysis platforms with hundreds of thousands of SNPs will encourage the implementation of advanced algorithms to test for more secluded genealogical relationships more openly between individuals. In addition, the demand for detecting malignant tumors has also increased. In the pediatric field, the short turnaround time without the need to hybridize SNP variations to massive deletions has led to enormous demand. As a result, the market is expected to grow as more genetic abnormalities are detected and treated.
SNP chips with high efficiency and accuracy are witnessing an increase in demand due to the constant need for technologically advanced and more sophisticated DTC genetic testing. A high preference for SNP chips can be attributed to their ability to measure dosage changes and DNA polymorphism, along with various applications such as the SNP microarray analysis that are vital for cancer research. Furthermore, an increasing need to minimize errors in DTC genetic testing is expected to drive the adoption of SNP technology, thereby providing an opportunity for the market growth.
Asia Pacific Direct-to-Consumer Genetic Testing Market Overview
The Asia Pacific direct-to-consumer genetic testing market is sub segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The market in this region is expected to grow at the fastest pace among all major regions in the world during the forecast period. The proliferation of the direct-to-consumer genetic testing market in Asia Pacific is attributed to the increasing need for superior treatment solutions, a rise in awareness of the early screening of genetic disorders, and the growing focus on research and development activities. Additionally, an upsurge in the R&D for genomics, a large pool of patients, and upgrades in healthcare infrastructure are projected to favor the growth of the direct-to-consumer genetic testing market in Asia Pacific during the forecast period.
Asia Pacific Direct-to-Consumer Genetic Testing Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Direct-to-Consumer Genetic Testing Market Segmentation
The Asia Pacific direct-to-consumer genetic testing market is segmented into test type, technology, distribution channel, and country.
Based on test type, the Asia Pacific direct-to-consumer genetic testing market is segmented into ancestry testing, predictive testing, nutrigenomics testing, carrier testing, and others. The ancestry testing market segment held the largest share in 2022.
In terms of technology, the Asia Pacific direct-to-consumer genetic testing market is categorized into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held the largest share in 2022.
Based on distribution channel, the Asia Pacific direct-to-consumer genetic testing market is bifurcated into online and offline. The online segment held a larger share in 2022.
Based on country, the Asia Pacific direct-to-consumer genetic testing market is segmented China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific direct-to-consumer genetic testing market in 2022.
Genesis Healthcare Co, Ancestry Genomics Inc, Myriad Genetics, Inc., Living DNA Ltd, 23andMe Inc, and Genetic Technologies Ltd are some of the leading companies operating in the Asia Pacific direct-to-consumer genetic testing market.
Table of Content